文献速递心脑血管急症重症综合管理与镇静镇痛

艾多沙班与维生素K拮抗剂在TAVR术后房颤中的比较

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
PubMed 文献 · N Engl J Med · 2021-08-28
一句话结论TAVR术后房颤患者中,艾多沙班在复合疗效终点上不劣于维生素K拮抗剂,但大出血发生率更高(HR 1.40),主要归因于消化道出血。

ENVISAGE-TAVI AF为多中心、前瞻性、随机、开放标签、裁定者设盲试验,纳入1426例TAVR成功后有房颤抗凝指征的患者(平均82.1岁,47.5%女性),比较艾多沙班与维生素K拮抗剂。主要疗效复合终点(全因死亡、心梗、缺血性卒中、系统性血栓栓塞、瓣膜血栓或大出血)发生率为17.3 vs 16.5/100人年(HR 1.05;95%CI 0.85-1.31;非劣效P=0.01),达到非劣效。大出血为9.7 vs 7.0/100人年(HR 1.40;95%CI 1.03-1.91;非劣效P=0.93),未达非劣效,差异主要因艾多沙班组消化道出血更多。全因死亡或卒中为10.0 vs 11.7/100人年(HR 0.85;95%CI 0.66-1.11)。

要点

  • TAVR成功后有房颤抗凝指征的患者,艾多沙班复合疗效终点不劣于维生素K拮抗剂(HR 1.05;95%CI 0.85-1.31;非劣效P=0.01)。
  • 艾多沙班组大出血发生率更高(9.7 vs 7.0/100人年;HR 1.40;95%CI 1.03-1.91),非劣效未成立(P=0.93),差异主要来自消化道出血。
  • 全因死亡或卒中:艾多沙班10.0 vs 维生素K拮抗剂11.7/100人年(HR 0.85;95%CI 0.66-1.11)。
  • 入组患者几乎均在TAVR前已有房颤,平均年龄82.1岁,属高出血风险人群,选择抗凝策略需权衡消化道出血。

适用人群与场景

  • TAVR成功后有流行性或新发房颤、具备口服抗凝指征的患者;平均年龄82.1岁,47.5%为女性,几乎均在TAVR前已有房颤。

诊断标准与关键阈值

  • 主要疗效终点为非劣效检验,非劣效界值为风险比95%CI上限不超过1.38。
  • 主要安全终点为大出血,同样按上述界值先行非劣效检验;仅当大出血非劣效且优效均成立后,才进行疗效优效检验。

处置流程与药物剂量

  • 原文未提及艾多沙班的具体剂量、给药途径、频次及维生素K拮抗剂的具体方案与目标值。

红旗征与不能漏的情况

  • 艾多沙班组大出血发生率更高(HR 1.40;95%CI 1.03至1.91),差异主要因消化道出血更多,需警惕TAVR术后抗凝患者的消化道出血风险。

研究设计与关键结果

  • 多中心、前瞻性、随机、开放标签、裁定者设盲试验,纳入1426例(每组713例),比较艾多沙班与维生素K拮抗剂。
  • 主要疗效复合终点(全因死亡、心梗、缺血性卒中、系统性血栓栓塞、瓣膜血栓或大出血):17.3 vs 16.5/100人年(HR 1.05;95%CI 0.85-1.31;非劣效P=0.01)。
  • 大出血:9.7 vs 7.0/100人年(HR 1.40;95%CI 1.03-1.91;非劣效P=0.93),非劣效未成立。
  • 全因死亡或卒中:10.0 vs 11.7/100人年(HR 0.85;95%CI 0.66-1.11)。

证据类型、等级与局限

  • 随机对照试验(RCT),多中心、前瞻性、开放标签、裁定者设盲;原文未给出证据等级或推荐强度。
  • 局限:开放标签设计;原文未提及其他局限。

对床旁实践的改变

  • TAVR术后房颤抗凝可考虑艾多沙班作为维生素K拮抗剂的替代,但需注意大出血风险更高,尤其消化道出血。
  • 因大出血非劣效未成立,不能据此认为艾多沙班在出血安全性上等同或优于维生素K拮抗剂。
  • 原文未提及具体适用与不适用人群的进一步限定。

指南或共识出处

  • ENVISAGE-TAVI AF试验(ClinicalTrials.gov NCT02943785),由Daiichi Sankyo资助;原文未提及指南或共识名称。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied.

METHODS: We conducted a multicenter, prospective, randomized, open-label, adjudicator-masked trial comparing edoxaban with vitamin K antagonists in patients with prevalent or incident atrial fibrillation as the indication for oral anticoagulation after successful TAVR. The primary efficacy outcome was a composite of adverse events consisting of death from any cause, myocardial infarction, ischemic stroke, systemic thromboembolism, valve thrombosis, or major bleeding. The primary safety outcome was major bleeding. On the basis of a hierarchical testing plan, the primary efficacy and safety outcomes were tested sequentially for noninferiority, with noninferiority of edoxaban established if the upper boundary of the 95% confidence interval for the hazard ratio did not exceed 1.38. Superiority testing of edoxaban for efficacy would follow if noninferiority and superiority were established for major bleeding.

RESULTS: A total of 1426 patients were enrolled (713 in each group). The mean age of the patients was 82.1 years, and 47.5% of the patients were women. Almost all the patients had atrial fibrillation before TAVR. The rate of the composite primary efficacy outcome was 17.3 per 100 person-years in the edoxaban group and 16.5 per 100 person-years in the vitamin K antagonist group (hazard ratio, 1.05; 95% confidence interval [CI], 0.85 to 1.31; P = 0.01 for noninferiority). Rates of major bleeding were 9.7 per 100 person-years and 7.0 per 100 person-years, respectively (hazard ratio, 1.40; 95% CI, 1.03 to 1.91; P = 0.93 for noninferiority); the difference between groups was mainly due to more gastrointestinal bleeding with edoxaban. Rates of death from any cause or stroke were 10.0 per 100 person-years in the edoxaban group and 11.7 per 100 person-years in the vitamin K antagonist group (hazard ratio, 0.85; 95% CI, 0.66 to 1.11).

CONCLUSIONS: In patients with mainly prevalent atrial fibrillation who underwent successful TAVR, edoxaban was noninferior to vitamin K antagonists as determined by a hazard ratio margin of 38% for a composite primary outcome of adverse clinical events. The incidence of major bleeding was higher with edoxaban than with vitamin K antagonists. (Funded by Daiichi Sankyo; ENVISAGE-TAVI AF ClinicalTrials.gov number, NCT02943785.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021. PMID: 34449183. doi:10.1056/NEJMoa2111016

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。